Tábata Takahashi França

Dr. Tábata Takahashi França

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2019 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
TFTábata Takahashi França
Tábata Takahashi França
LBLucila A. Barreiros
Lucila A. Barreiros
BABasel K. Al-Ramadi
Basel K. Al-Ramadi
HOHans D. Ochs
Hans D. Ochs
OMOtavio Marques
Otavio Marques
ACAntonio Condino-Neto
Antonio Condino-Neto
Introduction: CD40 ligand (CD40L) deficiency or X-linked Hyper-IgM syndrome is a severe primary immunodeficiency caused by mutations in the CD40L gene. Despite currently available treatments, CD40L-deficient patients remain susceptible to life-threatening infections and have poor long term survival. Areas covered: Here, we discuss clinical and immunological characteristics of CD40L deficiency as well as current therapeutic strategies used for patient management. This review highlights that beyond B cell defects, patients’ susceptibility to opportunistic pathogens might be due to impaired T cell and innate immune responses. In this context, we discuss how better knowledge of CD40L function and regulation may result in the development of new treatments. Expert opinion: Despite the introduction of hematopoietic stem-cell transplantation, immunoglobulin replacement, granulocyte colony-stimulating factor (G-CSF) administration, and prophylactic antibiotic therapies, life-threatening infections still cause high morbidity and mortality among CD40L-deficient patients. The reasons for this inadequate response to current therapies remains poorly understood, but recent reports suggest the involvement of CD40L–CD40 interaction in early stages of the innate immune system ontogeny. The development of novel gene therapeutic approaches and the use of redirected immunotherapies represent alternative treatment methods that could offer reduced morbidity and mortality rates for patients with CD40L deficiency.

5 October 2017 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLena F Schimke
Lena F Schimke
JHJames Hibbard
James Hibbard
RMRuben Martinez-Barricarte
Ruben Martinez-Barricarte
TKTaj Ali Khan
Taj Ali Khan
RCRicardo de Souza Cavalcante
Ricardo de Souza Cavalcante
ACAntonio Condino-Neto
Antonio Condino-Neto
Mutations in genes affecting interferon-γ (IFN-γ) immunity have contributed to understand the role of IFN-γ in protection against intracellular pathogens. However, inborn errors in STAT4, which controls interleukin-12 (IL-12) responses, have not yet been reported. Our objective was to determine the genetic defect in a family with a history of paracoccidioidomycosis. Genetic analysis was performed by whole-exome sequencing and Sanger sequencing. STAT4 phosphorylation (pSTAT4) and translocation to the nucleus, IFN-γ release by patient lymphocytes, and microbicidal activity of patient monocytes/macrophages were assessed. The effect on STAT4 function was evaluated by site-directed mutagenesis using a lymphoblastoid B cell line (B-LCL) and U3A cells. A heterozygous missense mutation, c.1952 A>T (p.E651V) in STAT4 was identified in the index patient and her father. Patient’s and father’s lymphocytes showed reduced pSTAT4, nuclear translocation, and impaired IFN-γ production. Mutant B-LCL and U3A cells also displayed reduced pSTAT4. Patient′s and father′s peripheral blood mononuclear cells and macrophages demonstrated impaired fungicidal activity compared with those from healthy controls that improved in the presence of recombinant human IFN-γ, but not rhIL-12. Our data suggest autosomal dominant STAT4 deficiency as a novel inborn error of IL-12–dependent IFN-γ immunity associated with susceptibility to paracoccidioidomycosis.

1 March 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
OMOtavio Marques
Otavio Marques
RRRodrigo Nalio Ramos
Rodrigo Nalio Ramos
LSLena F. Schimke
Lena F. Schimke
TKTaj Ali Khan
Taj Ali Khan
EAEduardo Pinheiro Amaral
Eduardo Pinheiro Amaral
ACAntonio Condino-Neto
Antonio Condino-Neto

1 November 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
OMOtavio Marques
Otavio Marques
TFTábata Takahashi França
Tábata Takahashi França
AAAshraf Al-Sbiei
Ashraf Al-Sbiei
LSLena Friederike Schimke
Lena Friederike Schimke
TKTaj Ali Khan
Taj Ali Khan
ACAntonio Condino-Neto
Antonio Condino-Neto

4 May 2018 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
TFTábata Takahashi França
Tábata Takahashi França
LLLuiz F. B. Leite
Luiz F. B. Leite
TMTiago A. Maximo
Tiago A. Maximo
CLChristiane G. Lambert
Christiane G. Lambert
NZNuria B. Zurro
Nuria B. Zurro
ACAntonio Condino-Neto
Antonio Condino-Neto
Mutations in the CD40 ligand (CD40L) gene (CD40LG) lead to X-linked hyper-IgM syndrome (X-HIGM), which is a primary immunodeficiency (PID) characterized by decreased serum levels of IgG and IgA and normal or elevated IgM levels. Although most X-HIGM patients become symptomatic during the first or second year of life, during which they exhibit recurrent infections, some patients exhibit mild phenotypes, which are usually associated with hypomorphic mutations that do not abrogate protein expression or function. Here, we describe a 28-year-old man who initially presented with recurrent infections since the age of 7 years, when he exhibited meningitis caused by Cryptococcus neoformans. The patient had no family history of immunodeficiency, and based on clinical and laboratory presentation, he was initially diagnosed with common variable immunodeficiency (CVID). In subsequent years, he displayed several sporadic episodes of infection, including pneumonia, pharyngotonsillitis, acute otitis media, rhinosinusitis, fungal dermatosis, and intestinal helminthiasis. The evaluation of CD40L expression on the surface of activated CD3+CD4+ T cells from the patient showed decreased expression of CD40L. Genetic analysis revealed a novel de novo mutation consisting of a 6-nucleotide insertion in exon 1 of CD40LG, which confirmed the diagnosis of X-HIGM. In this report, we describe a novel mutation in the CD40L gene and highlight the complexities of PID diagnosis in light of atypical phenotypes and hypomorphic mutations as well as the importance of the differential diagnosis of PIDs.

3 May 2022 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
LBLucila Akune Barreiros
Lucila Akune Barreiros
JSJusley Lira Sousa
Jusley Lira Sousa
CGChristoph Geier
Christoph Geier
ALAlexander Leiss-Piller
Alexander Leiss-Piller
MKMarilia Pylles Patto Kanegae
Marilia Pylles Patto Kanegae
ACAntonio Condino-Neto
Antonio Condino-Neto